LUMIRABIO at CIBE Guangzhou 2026: Peptide API Conversations Across the Beauty Supply Chain

The 71st CIBE Guangzhou at a glance

The 71st China (Guangzhou) International Beauty Expo is scheduled for 4–6 September 2026 at the China Import and Export Fair Complex in Guangzhou.

The organizer describes a cross-category event covering beauty and skincare products, daily-use products, nail and lash categories, beauty tools, instruments and equipment, raw materials and excipients.

Organizer reporting says more than 3,800 exhibitors and brands are expected across the exhibition.

That scale matters because product concepts, ingredients, manufacturing resources, devices, packaging and distribution channels can be evaluated in the same commercial setting.

For regulated and evidence-sensitive materials, however, visibility is only the beginning.

A trade-show category does not determine a material's legal status, permitted use, quality standard, regulatory pathway or suitability for a particular market.

Why Hall 5.2 puts ingredient classification in focus

CIBE's official Hall 5.2 preview lists home beauty devices, hair and personal care, oral beauty, oral care, maternal and infant categories, and beauty raw materials.

It also identifies a dedicated beauty-ingredient area in Area A, Hall 5.2, operating during the three show days.

This mix creates useful upstream-to-downstream conversations.

Brand, formulation, sourcing and channel teams can compare how an ingredient concept moves toward a product brief, what documentation is required, and which claims or markets change the development pathway.

It also makes classification discipline essential.

Pharmaceutical APIs, cosmetic ingredients, food ingredients, finished medicines and consumer products are not interchangeable categories.

LUMIRABIO's exhibition communication therefore stays within qualified B2B peptide API review and does not imply suitability for cosmetics, oral-beauty products, direct consumer use or any finished dosage form.

Meet LUMIRABIO in Area A, Hall 5.2, Booth J08A

LUMIRABIO's confirmed exhibitor materials place the team at Booth J08A in Area A, Hall 5.2.

The booth will provide a setting for pharmaceutical, biotechnology, CMC, quality, regulatory and procurement teams to frame project-specific peptide API questions.

The public portfolio is intentionally focused on three molecular identities: Semaglutide API, Tirzepatide API and Retatrutide API.

Their status and project boundaries remain distinct.

A shared peptide label does not make their exact form, specification, documentation, availability or market eligibility identical.

No exhibition conversation should be read as a public offer, personal-use route or automatic confirmation of supply.

Any next step depends on the customer entity, intended use, project stage, target market, requested material, quantity, documentation and applicable legal and intellectual-property review.

Three peptide API identities, three separate qualification paths

Semaglutide and tirzepatide are established molecular identities used as active ingredients in approved finished medicines in defined jurisdictions and indications.

A finished medicine's approval does not automatically establish the status, source eligibility or documentation sufficiency of a third-party API for a particular project.

For a Semaglutide API or Tirzepatide API discussion, teams should confirm the precise material form, reference identity, specification, analytical methods, related-peptide strategy, batch evidence, responsible site and entity, destination and intended use.

Those fields are confirmed against the proposed project rather than inferred from a molecule name.

Retatrutide remains investigational.

LUMIRABIO presents it only within an investigational API and qualified-institution boundary.

It is not approved for public use and is not presented as a consumer product, finished medicine or generally available treatment.

Questions to bring to an ingredient or API meeting

A short project brief helps both sides use exhibition time for questions that affect feasibility and qualification.

Useful inputs include:

• The legal product category, intended use, development stage and target jurisdiction.
• The exact molecule, requested form, reference standard, specification and estimated quantity.
• Identity, purity, related substances, counter-ion, water, residual-solvent and stability questions relevant to the project.
• Required specifications, CoAs, methods, traceability records and other quality or regulatory documents.
• The proposed manufacturing, release and supply responsibilities, including the applicable site and legal entity.
• Packaging, storage, delivery, change-control, intellectual-property and import requirements.

From a cross-sector introduction to a qualified project

A beauty-industry exhibition can surface new questions about ingredients, evidence, cross-border channels and adjacent technical needs.

It should not collapse the distinction between regulated material categories.

After an initial conversation, a viable peptide API project moves through written scope definition, confidentiality where required, technical and analytical review, quality-document alignment, regulatory and intellectual-property assessment, and commercial qualification.

Conclusions apply to the defined project, not to every use or market.

Visitors can meet LUMIRABIO at Booth J08A from 4–6 September 2026.

Bringing a concise project brief will make the discussion more useful and help identify the right technical and compliance owners for follow-up.